Patients with metastatic colorectal cancers are needed for a study to research an experimental combination of 2 drugs

IRB/UVA Tracking #
Principal Investigator
Matthew J Reilley
Tammy Battaglia
Contact Phone
Official Trial Title
LCCC 1717: Phase II single-arm study of the combination of palbociclib and cetuximab in KRAS/NRAS/BRAF wild-type metastatic colorectal cancer
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have metastatic colorectal cancer. The purpose of this study to evaluate the experimental combination of 2 FDA approved drugs (cetuximab + palbociclib) in patients with metastatic colorectal cancer. The safety and effects of the experimental drug combination will be evaluated for this study.

Participation is approximately 4 months of drug treatment and possibly longer, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:


You will not receive any compensation/reimbursement for this study.